PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

This trial is studying two targeted cancer drugs — a PARP inhibitor and a drug that blocks blood vessel growth (angiogenesis inhibitor) — in women with a newly diagnosed type of ovarian, fallopian tube, or peritoneal cancer that has a specific DNA repair flaw called homologous recombination deficiency (HRD). Researchers want to know if combining both drugs works better than the PARP inhibitor alone. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer - Your tumor has tested positive for a DNA repair problem called HRD - You are well enough to carry out light activity (good general health status) - You are able to undergo a diagnostic or surgical procedure **You may NOT be eligible if...** - You have another active cancer - You are pregnant or breastfeeding - Your cancer has already progressed during treatment Talk to your doctor to see if this trial is right for you.